Subacute Doxorubicin-Induced Cardiomyopathy with Reduced Ejection Fraction and Optimal Recovery of Left Ventricular Ejection Fraction After Medical Heart Failure Treatment

Background: Doxorubicin, an anthracycline compound commonly used as a chemotherapeutic agent is well known to cause cardiotoxicity. It is generally regarded that once cardiotoxicity occurs, the damage done would be irreversible. Early-onset cardiomyopathy induced by doxorubicin often occurs during the 1st year after the completion of chemotherapy. Medical therapy use has been by large uncertain in its efficacy, but not all hope is lost. We...